Gilead's twice-yearly shot to prevent HIV succeeded in a late-stage trial.briefly passed the 5,500 level for the first time on Thursday before pulling back. The broad market index closed down 0.25% while the, meanwhile, rose 299.90 points, or 0.77%, good for its best day this month. Despite turning negative on Thursday, stocks are headed for a winning week, with the S&P 500 and Nasdaq notching new records earlier in the week.
If that trial goes well, the company could bring the shot to market as soon as late 2025. Shares of the company rose about 8.5% and notched their best day since 2022.The Truth Social website on a smartphone arranged in the Brooklyn borough of New York, US, on Friday, Nov. 18, 2022.on Thursday, deepening a sell-off for the stock. The stock saw massive trading volume for the day, as more than 13.2 million shares of Trump Media changed hands — over three times its 30-day average trading volume.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: NBCLA - 🏆 319. / 59 Read more »
Source: CNBC - 🏆 12. / 72 Read more »